Susquehanna Maintains Positive rating on Advanced Life Sciences (ADLS), Analyst Lowers Price Target
ADLS Hot Sheet
Rating Summary:0 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 5 | Down: 3 | New: 10
Susquehanna maintains Positive rating on Advanced Life Sciences Holdings, Inc. (Nasdaq: ADLS). Price target lowered from $3 to $2.50.
"We are disappointed that ADLS has not signed a U.S. marketing partner for Cethromycin. We were not surprised that the company waited until after the quarter closed to inform us of the lack of a U.S. deal. We are disappointed that cash will likely continue to be an overhang for the company. The company is scraping by with an existence, but did meet its guidance for filing the Cethromycin NDA with the FDA for mild-to-moderate community acquired pneumonia (CAP) in 3Q08. By announcing the filing on the first day of 4Q08, we are led to believe the work came down to the wire. The company is looking for a U.S. marketing partner, but announced an Asia-Pacific partnership with limited up-front payments. We would like to believe a U.S. partnership is coming. Valuation is attractive, and we remain with a Positive rating."
Advanced Life Sciences Holdings, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of drugs in the areas of infectious disease, oncology and inflammation.
"We are disappointed that ADLS has not signed a U.S. marketing partner for Cethromycin. We were not surprised that the company waited until after the quarter closed to inform us of the lack of a U.S. deal. We are disappointed that cash will likely continue to be an overhang for the company. The company is scraping by with an existence, but did meet its guidance for filing the Cethromycin NDA with the FDA for mild-to-moderate community acquired pneumonia (CAP) in 3Q08. By announcing the filing on the first day of 4Q08, we are led to believe the work came down to the wire. The company is looking for a U.S. marketing partner, but announced an Asia-Pacific partnership with limited up-front payments. We would like to believe a U.S. partnership is coming. Valuation is attractive, and we remain with a Positive rating."
Advanced Life Sciences Holdings, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of drugs in the areas of infectious disease, oncology and inflammation.
You May Also Be Interested In
- Barclays Maintains an 'Equalweight' on J. C. Penney (JCP); Slashing PT on Disappointing Results
- UBS Maintains a 'Neutral' on Ralcorp Holdings (RAH); Trimming Numbers After Q2 Miss
- Deutsche Bank Cuts Price Target and EPS Estimates on J. C. Penney (JCP); There's Only Two Ways This Can Go
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Susquehanna International Group of CompaniesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
